stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Free cash flow
Viridian Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$276.9M, compared with −$232.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$343.4M. Over the past ten years it has ranged from −$276.9M (fiscal 2025) to −$7.0M (fiscal 2015) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Viridian Therapeutics, Inc. ranks 575th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$276.9M | — |
| FY2024 | −$232.8M | — |
| FY2023 | −$185.1M | — |
| FY2022 | −$94.6M | — |
| FY2021 | −$54.8M | — |
| FY2020 | −$29.8M | — |
| FY2019 | −$36.1M | — |
| FY2018 | −$27.3M | — |
| FY2017 | −$28.4M | — |
| FY2016 | −$15.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$93.1M | — |
| Jun 2026 | −$106.6M | — |
| Mar 2026 | −$119.7M | — |
| Dec 2025 | −$24.0M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | $32.4M |
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| ELVN Enliven Therapeutics, Inc. compare | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. | −$343.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$349.8M |
| DNLI Denali Therapeutics Inc. compare | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement